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ABSTRACT
Triplebodies are antibody-derived recombinant proteins carrying 3 antigen-
binding domains in a single polypeptide chain. Triplebody SPM-1 was designed for 
lysis of CD19-bearing malignant B-lymphoid cells through the engagement of CD16-
expressing cytolytic effectors, including NK and gd T cells.
SPM-1 is an optimized version of triplebody ds(19-16-19) and includes 
humanization, disulfide stabilization and the removal of potentially immunogenic 
sequences. A three-step chromatographic procedure yielded 1.7 - 5.5 mg of purified, 
monomeric protein per liter of culture medium. In cytolysis assays with NK cell 
effectors, SPM-1 mediated potent lysis of cancer-derived B cell lines and primary 
cells from patients with various B-lymphoid malignancies, which surpassed the ADCC 
activity of the therapeutic antibody Rituximab. EC50-values ranged from 3 to 86 pM. 
Finally, in an impedance-based assay, SPM-1 mediated a particularly rapid lysis of 
CD19-bearing target cells by engaging and activating both primary and expanded 
human gd T cells from healthy donors as effectors.
These data establish SPM-1 as a useful tool for a kinetic analysis of the cytolytic 
reactions mediated by gd T and NK cells and as an agent deserving further development 
towards clinical use for the treatment of B-lymphoid malignancies.
INTRODUCTION
CD19 is a type I transmembrane glycoprotein and 
a signaling receptor of the immunoglobulin superfamily. 
It is a component of the B cell receptor (BCR) co-
complex, and is expressed from early to late stages of 
B cell development. Signaling through CD19 promotes 
proliferation and differentiation [1–4]. The antigen is 
particularly promising for targeted immunotherapy of 
B-lymphoid malignancies, because of its relatively high 
and lineage-specific expression on B cells of different 
maturation stages and its presence on the surface of cancer 
progenitor cells [5–7]. However, the results of initial 
clinical trials with CD19-antibodies were disappointing [5, 
8], presumably due at least in part to a far lower surface 
density of CD19 on the malignant cells than of CD20 
on lymphoma cells, the target antigen for the clinically 
successful antibody Rituximab.
A second generation of improved CD19-targeting 
proteins and cellular agents has been developed, which 
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includes Fc- and glyco-engineered immunoglobulins, 
such as the antibodies XmAb5574 (MOR208) and 
MEDI-551 [9, 10], the bispecific T cell engager (BiTE®) 
Blinatumomab (Blincyto®) [11, 12], and the adoptive 
transfer of genetically modified T cells, obtained by 
stable transfection with chimeric antigen receptors 
(CARs). Genetically modified CAR-T cells (CAR-
Ts) have been remarkably successful in the treatment 
of various B-lymphoid malignancies, in particular of 
Acute Lymphoblastic Leukemia (ALL) in children 
and young adults with poor prognosis [13–16]. CD19 
therefore clearly is a useful target for antigen-specific 
immunotherapy, provided an appropriate molecular format 
of the therapeutic agent is chosen.
BiTE and CAR-T cell approaches rely on cytotoxic 
T lymphocytes (CTLs) for the elimination of cancer 
cells [11, 13–16]. Although highly effective in many 
cases, these approaches still leave room for future 
improvements. In rare cases, undesirable adverse events 
have been reported after treatment of patients with CD19-
directed BiTEs and CD19-directed CAR-Ts. These include 
cytokine release syndromes and involvement of the central 
nervous system [17] as well as tumor lysis syndrome 
and the occasional outgrowth of target antigen-negative 
tumor cell clones (“antigen-loss” or “escape” variants) 
[12, 17, 18]. A short serum half-life in the case of BiTEs, 
potentially durable lymphopenia in the case of CARTs and 
finally, the associated high costs limit the availability of 
these therapies for a significant segment of patients.
The use of antibodies for therapeutic purposes, on 
the other hand, is well-established and effective, and is 
generally less expensive, but also suffers from certain 
limitations. These agents rely on the presence of Fc-
receptor-bearing effector cells, which can be activated 
by the mediator protein to assemble a productive synapse 
with the target cell. In some cases, the needed effector 
cells are not available in sufficient quantity and quality 
at certain stages of disease development. An example are 
limiting numbers of functionally active NK cells in the 
bone marrow of AML patients at diagnosis, which limit 
the use of IgGs as front-line therapeutic agents [19–22]. 
Immunoglobulins further suffer from limited penetration 
into solid tumor tissues, owed to their large mass [23–25].
To address some of these limitations of mono-
targeting IgGs, our team has developed the molecular 
format of single chain triplebodies. These proteins consist 
of 3 single chain variable antibody fragments (scFvs) 
connected by flexible (G4S)n linkers [26–31]. Triplebodies 
are anticipated to have improved pharmacokinetic 
properties due to their smaller size of approximately 90 
kD. Based on experimental and theoretical data from other 
groups, this is expected to result in a faster equilibration of 
these molecules in the mammalian blood circulation and in 
an easier penetration into solid tumor tissues compared to 
full-length antibodies [23, 32, 33]. Furthermore, triplebody 
SPM-2 was shown to mediate an efficient elimination 
of AML blasts from an AML patient in remission by 
autologous NK cells [34].
Triplebodies developed so far were designed 
for bivalent binding of a tumor cell via their two distal 
scFvs, and for monovalent binding to a trigger molecule 
on a cytolytic effector cell through their central scFv. 
Effector cells engaged by triplebodies to date include NK 
cells, CTLs, and neutrophilic granulocytes, which were 
activated for cytolysis via the triggers CD16, CD3ε, and 
CD64, respectively [35]. CD16, the human Fcγ-receptor 
III (FcγRIII), is expressed by NK cells, macrophages, γδ 
T cells and a subset of cytokine-stimulated dendritic cells 
(DCs). Upon cross-linking, signaling via CD16, which 
associates with the FcR γ-chain or CD3ζ, elicits potent 
effector functions including ADCC and phagocytosis [36].
NK cells and γδ T cells are capable of recognizing 
and eliminating malignant cells in a natural killing mode 
in the absence of mediator proteins such as antibodies. NK 
cells respond to the absence of MHC class I proteins on 
cancer cells (“missing self”). γδ T cells are independent of 
MHC : peptide recognition, but can react to non-peptidic 
phosphoantigens, which are preferentially displayed on the 
surface of cancer cells. Therefore, both of these effector 
cell classes can bypass immune evasion of cancer cells 
by downregulation of MHC class I [37, 38]. In addition, 
NK cells and γδ T cells are major anti-viral effectors after 
transplantation of hematopoietic stem cells (HSCT), but 
do not cause graft-versus-host-disease (GvHD) [37]. 
Enhancing the cytolytic activity of NK cells and γδ T 
cells via CD16-triggering therapeutic agents therefore is 
a promising strategy for cancer treatment, which may also 
lead to a systemic cellular immune response following an 
initial lysis of cancer cells by ADCC, in the sense of a 
tumor-vaccination effect.
The capacity to recruit γδ T cells as cytolytic 
effectors has not yet been established for triplebodies 
triggering through CD16, although it had been reported 
for other agents in related molecular formats, including the 
Fc-engineered CD19-antibody 4G7SDIE and the bispecific 
CD19-targeting fusion protein N19-C16 [39–41]. 
Therefore, we anticipated that a similar result may also be 
obtained for corresponding triplebodies, but experimental 
verification of this hypothesis was still needed. These 
agents have different sizes and space-filling properties, 
and may therefore differ in their steric access to CD16 
epitopes on NK and γδ T cells. To test this hypothesis, the 
previously described triplebody ds(19-16-19) [26], with 2 
binding sites for CD19 and one for CD16, was humanized 
and stabilized, and the new agent was named SPM-1. The 
protein was purified, characterized and compared here 
in NK cell-based ADCC assays to other CD19-specific 
agents in related molecular formats. In support of the 
hypothesis, SPM-1 was found capable indeed of mediating 
lysis of CD19-bearing target cells in combination 
with human γδ T cells as effectors in ADCC assays. In 
these studies we also observed that SPM-1 mediated a 
particularly rapid lysis of substrate-bound CD19-bearing 
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target cells in a time-resolved, impedance-based assay, 
the XCelligence® assay [41, 42]. This stimulating finding 
calls for additional future studies of the kinetics of the 
ADCC process mediated by antibody-derived agents with 
different molecular architecture, which will likely lead 
to a better understanding of the unusually high cytolytic 
potential of triplebodies compared to some of the related 
bi-specific agents [26].
RESULTS
Design and production of triplebody SPM-1
Triplebody SPM-1 was constructed based on the 
published parental triplebody ds(19-16-19) [26]. The scFv 
domains of the parental protein were derived from the 
murine monoclonal antibodies 4G7 and 3G8. To minimize 
immunogenicity, the CD16- and CD19-directed scFv 
sequences were humanized by CDR grafting [43, 44] plus 
subsequent adjustment of the framework. The humanized 
CD16 scFv was then disulfide-stabilized, whereas the 2 
humanized CD19-binding domains were used without 
further stabilization, because this protein was sufficiently 
stable compared with disulfide-stabilized variants, which 
have also been studied (Figure 1A and additional data not 
shown). The cDNA coding sequences for the 2 CD19-
specific scFvs were adjusted by mutations in the wobble 
bases to minimize homologous recombination in the 
producer cells, and thus to improve production yields of 
the desired protein. This procedure reduced the occurrence 
of truncated variants, which had been observed prior to 
this optimization.
SPM-1 was expressed in Freestyle™ 293-F cells 
(Life Technologies) and was purified in a 3-step procedure, 
which included capture from culture supernatants by zinc 
ion affinity chromatography followed by anion and cation 
exchange chromatography. This capture step and the ion 
exchange chromatography protocol followed industry 
standard procedures, and the downstream purification 
process is scalable and suitable for commercial production. 
Yields ranged from 1.7 - 5.5 mg of purified protein/L of 
culture supernatant in different production runs (Table 1). 
Purified SPM-1 eluted as a single monomeric peak in size 
exclusion chromatography profiles and was highly pure 
as evidenced by SDS-polyacrylamide gel electrophoresis 
(Figure 1B, 1C).
Figure 1: Structural characteristics and purification of triplebody SPM-1. A. CD19-specific scFv domains shown in light 
grey; CD16-specific scFv domain in dark grey. B. After purification with the 3-step chromatographic procedure described in Methods, 
SPM-1 eluted in size exclusion chromatography profiles (SEC) as a single monodisperse peak corresponding to the molecular mass of an 
SPM-1 monomer. Species of higher molecular mass (aggregates) were absent/below detection limit. C. Fractions from the SEC elution 
profile (eluting between the dashed lines in B) were analyzed by SDS-PAGE and stained with Coomassie blue. The preparation was of high 
purity; higher and lower molecular mass species were absent or only very minor contaminants.
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Binding characteristics of SPM-1
Specificity of SPM-1 binding to CD19 and CD16 
was established by cytofluorimetry with suitable control 
antibodies and control cells (unpublished data). The 
monovalent affinity of SPM-1 for CD16 and the bivalent 
avidity for CD19 were measured by determining the 
equilibrium binding constants (KD) by flow cytometry 
with CD16- or CD19-bearing human cells as previously 
described [45, 46]. The KD value of SPM-1 for CD16 was 
12.0 ± 1.5 nM, which was lower than the value of 58.6 
± 4 nM reported for the parental triplebody ds(19-16-
19). Therefore, the humanized plus disulfide-stabilized 
CD16 binding domain carried in SPM-1 displayed 4- to 
5-fold stronger binding to human CD16 on living cells 
than the corresponding domain of the parental protein. 
The KD value of SPM-1 for CD19 (17.5 ± 0.4 nM) 
was comparable to the value measured for the parental 
protein (13.0 ± 1.2 nM; Table 1) [26], and therefore, the 
humanization procedure has not significantly altered the 
binding avidity of the second-generation triplebody for 
CD19.
Cytolytic activity of SPM-1 in combination with 
human NK cells
The ability of SPM-1 to mediate cytolysis of human 
cancer cells by NK cells from unrelated healthy donors 
was tested in standardized redirected lysis (RDL) assays 
against malignant human B-lymphoid cell lines at an 
effector-to-target cell (E : T) ratio of 2 : 1. The target 
cell lines represented different classes of B-lymphoid 
neoplasias and carried different mean surface densities 
of CD19 (Table 2). All tested cell lines displayed a dose-
dependent cytolytic response to treatment with SPM-1 
plus NK cells (Figure 2). The potential of these cell lines 
for specific lysis was weakly correlated with their mean 
target antigen density: the SEM line with the highest CD19 
density displayed the strongest cytolytic response, whereas 
the ARH-77 line with the lowest density displayed the 
weakest response. No specific lysis was observed, when 
the specificity control triplebody Her2-16-Her2 was used 
(Figure 2), as expected, because Her2 is not expressed on 
these target cells. The measured EC50-values of 5.6 pM 
for the SEM line and 79.4 pM for ARH-77 cells (Table 1) 
were in the same range as the values previously reported 
for the non-humanized parental triplebody, which were 4.1 
and 29 pM, respectively [26]. Therefore, in combination 
with NK cells from an unrelated healthy donor, SPM-1 
displayed overall similar cytolytic potential for malignant 
B-lymphoid cell lines as the parental triplebody.
SPM-1 mediates stronger lysis of some primary 
cancer cell samples by NK cells than the 
therapeutic antibody Rituximab (MabThera®)
The ability of SPM-1 to mediate cytolysis of a panel 
of primary B-lymphoid cancer cell samples in conjunction 
with NK cells was compared with the corresponding ability 
of the clinically successful CD20 antibody Rituximab 
(MabThera®). Peripheral blood samples from 2 newly 
diagnosed B-CLL patients, from a relapsed B-CLL patient 
4 years after treatment with Rituximab, from a Non-
Hodgkin lymphoma patient with leukemic progression, 
and from an adolescent patient with a mixed phenotype 
acute leukemia (not otherwise specified) (MPAL (NOS)) 
were collected. Mean target antigen densities on the blast 
surfaces were determined by calibrated cytofluorimetry, 
and all blast populations with exception of the MPAL 
(NOS) sample were double-positive for CD19 and CD20 
at varying mean densities (Table 3). The MPAL (NOS) 
sample was CD20-negative. The newly diagnosed B-CLL 
and NHL samples displayed dose-dependent responses to 
both SPM-1 and Rituximab, whereas the MPAL (NOS) 
sample responded only to treatment with SPM-1 (Figure 
3). Blasts from the relapsed B-CLL patient did not respond 
to treatment with Rituximab under these conditions, 
although they expressed CD20 on their surface, and these 
cells were therefore not antigen-loss escape variants. They 
displayed a weak, but clearly measurable dose-dependent 
response to treatment with SPM-1. Therefore, they still 
were capable of responding to NK-mediated lysis, and 
thus their failure to respond to treatment with Rituximab 
must have been due to other causes. The EC50-values for 
SPM-1 were 5- to 430-fold lower than those for Rituximab 
under these experimental conditions (Table 3).
SPM-1 mediates comparable cytotolytic activity 
by NK cells as related Fc-engineered antibody-
derived agents
After having established that triplebody SPM-1 was 
capable of mediating effective lysis of cancer cells via the 
CD16-specific scFv domain in ADCC experiments with 
Table 1: Biological activity and antigen affinity of triplebody SPM-1
Construct Yield [mg/L cell culture]
Biol. Activity (SEM) 
EC50 [pM]
Affinity CD16 [nM] Avidity CD19 [nM]
SPM-1 1.7 - 5.5 11 ± 3 12.0 ±1.5 17.5 ± 0.4
The affinity is the equilibrium binding constant KD for monovalent binding to CD16 on stably transfected CHO-CD16 cells; 
the avidity is the KD value of the molecule for bivalent binding to CD19-bearing SEM target cells.
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human NK cells, we asked how strong this activity was 
compared with related molecular formats of antibody-
derived proteins, which carry an Fc portion optimized 
for ADCC activity by suitable point mutations. To this 
effect we employed 2 CD19-specific minibodies, one with 
an engineered Fc-domain, mutated for optimized ADCC 
activity, the other with the non-mutated Fc-portion from 
the parental human IgG1 antibody. In addition, we had 
access to the Fc-engineered CD19-antibody 4G7SDIE 
[39, 41] for comparative cytotoxicity studies, which 
carried some of the same mutations in its Fc-portion as 
the optimized minibody (Figure 4A). Standardized 3 hr 
cytolysis assays were performed with NK cells from a 
healthy donor at an E : T ratio of 2 : 1 against SEM (pro-B 
ALL) and Namalwa (Burkitt lymphoma) target cells. No 
difference was observed between the dose-response of the 
target cells to treatment with SPM-1 or the Fc-engineered 
CD19 antibody 4G7SDIE and the Fc-engineered 
minibody, while treatment with the non-Fc-engineered 
minibody was  ineffective (Figure 4B). Remarkably, SPM-
1 and the Fc-engineered 4G7SDIE antibody produced a 
similar degree of maximum specific lysis in this endpoint 
assay, and both were active with similar EC50-values, 
while clear differences in the kinetics of their action in 
ADCC experiments with γδ T cells as effectors were 
observed in the impedance-based, time-resolved assays 
described below (Figure 6; Supplementary Figure S1). 
Therefore, release assays measuring only the endpoint 
of cytotoxicity integrated over an entire measurement 
interval, typically of 3 - 4 hrs, fail to reveal kinetic details 
of the reaction, which however are likely to be important 
for an understanding of the in vivo activity of these agents 
in animal models and human recipients.
Activation of non-pre-stimulated γδ T cells from 
peripheral blood of healthy donors by SPM-1 
plus target cells
Human γδ T cells express CD16 and are capable of 
mediating ADCC of malignant targets in combination with 
CD19-antibodies and the antibody-derived bispecific agent 
N19-C16 [39–41]. Therefore here we asked, whether 
primary human γδ T cells from healthy donors, not pre-
stimulated by other means, can be activated for cytolysis 
by exposure to SPM-1 plus target cells. Peripheral blood 
mononuclear cells (PBMCs) were isolated from platelet-
pheresis products from healthy donors and the fraction of 
γδ T cells in this population was (2.3 ± 1.2) % on average. 
These low frequencies necessitated an indirect detection 
method for the activation of primary untreated γδ T cells. 
To this effect, CD19-bearing pro-B (SEM) and pre-B 
ALL (NALM-6) cells were first incubated overnight with 
primary samples of γδ T cells, and subsequently SPM-
1 or control agents were added and ADCC activity was 
indirectly monitored by measuring the appearance of the 
degranulation marker CD107a on the surface of the γδ T 
cells. In addition, intracellular concentrations of TNFα 
and IFN-γ were measured by cytofluorimetry as markers 
for activation towards cytolysis. In the absence of CD19-
bearing targets, γδ T cells of only a few sensitive donors 
displayed a weak elevation of CD107a on their surface 
and a small increase in intracellular TNFα after addition of 
SPM-1. However, after overnight incubation with CD19-
bearing target cells, γδ T cells from several donors showed 
a clear increase in cell surface CD107a and intracellular 
TNFα and IFN-γ after addition of SPM-1, and thus 
showed clear evidence for activation towards cytolysis by 
SPM-1 plus target cells (Figure 5).
SPM-1 mediates target cell lysis by both primary 
non-expanded and ex vivo expanded γδ T cells 
from healthy donors
To assess whether γδ T cells are capable of lysing 
CD19-bearing target cells by ADCC in combination with 
SPM-1 or control agents, and to observe the progress of 
this reaction in real time, viability of CD19-expressing, 
adherent MCF7-CD19 tm cells was monitored with the 
xCelligence assay system [41, 42]. This assay was initially 
used here with freshly isolated, non-expanded γδ T cells 
from 2 healthy donors. The γδ T cells were enriched in 
one case by positive selection with immunomagnetic 
(MACS) beads and reached a purity of 97 %, but the 
absolute number of cells collected in this manner was 
low. Specific lysis was obtained in combination with both 
SPM-1 and the CD19 antibody 4G7SDIE, in particular at 
Table 2: Surface expression of CD19 and EC50 values for RDL by SPM-1 with different malignant B lymphoid cell 
lines as targets
Cell Line Subtype of malignancy CD19 density [#] EC50 (range) [pM]
SEM Pro-B (mixed lineage) 42,600 ± 10,700 5.6 (2.5 – 10)
NALM-6 Pre-B 26,700 ± 11,400 6.1 (1.8 – 17.3)
RAJI Burkitt’s Lymphoma 31,900 ± 22,800 16.5 (5.4 – 38.5)
ARH-77 Mature B (myeloma) 2,400 ± 1,200 79.4 (38 – 645.3)
Antigen densities are given in copy numbers per cell.
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high E : T ratios of 10 : 1 and 20 : 1, but not with the 
control triplebody SPM-2 (data not shown). These results 
are consistent with earlier reports, in which specific lysis 
of MCF7-CD19 tm cells with similarly enriched non-
expanded γδ T cells from healthy donors mediated by the 
4G7SDIE antibody had been reported [41]. In conclusion, 
SPM-1 was capable of mediating ADCC of these adherent 
target cells by non-expanded γδ T cells from a healthy 
donor, but the available cell numbers were too low to 
permit a systematic study. Therefore, the experiments, 
which are described below (Figure 6; Supplementary 
Figure S1), were performed with ex vivo expanded γδ T 
cells.
For this purpose PBMCs from healthy volunteers 
obtained by leukapheresis were first expanded ex vivo 
in the presence of rhIL-2 and zolendronate as described 
previously [41]. After 12 -14 d in culture the total number 
of expanded cells was increased only marginally (by about 
30 %), but the fraction of γδ T cells within the expanded 
population was increased by about 20 - 30-fold from 
typically 2 - 3 % to 35.9 – 60.6 %. The fraction of CD16-
bearing γδ T cells in the expanded cell population was 
around 36 % for the sample from Donor 2. γδ T cells were 
then isolated from this population with immunomagnetic 
beads, which resulted in highly pure γδ T cells in sufficient 
numbers. The batch derived from Donor 2 was 98 % pure 
at this stage and was incubated once more overnight 
with IL-2 to remove contaminants resulting from the 
MACS enrichment procedure. This population was still 
heterogeneous with regard to CD16 antigen density on the 
cell surface. xCelligence assays were then performed with 
these cells using either SPM-1 or 4G7SDIE or control 
proteins as mediators of lysis. While the morphological 
and physiological properties of γδ T cells are likely 
to be affected by this ex vivo expansion, the use of this 
expanded population still permits us to conclude, whether 
γδ T cells as a defined T cell subset are capable in principle 
of achieving target cell lysis mediated by SPM-1.
Specific lysis values were calculated from the 
raw data and plotted for 3 different donors of γδ T cells 
at different E : T ratios as a function of time (Figure 6). 
Addition of SPM-1 caused a rapid increase in specific 
target cell lysis by γδ T cells from Donors 2 and 4 
within the first 3 hrs. Close to 100 % of specific lysis 
was achieved within 12 hrs. By contrast, γδ T cells from 
Donor 3 did not produce a similarly rapid lysis during the 
first hours, but showed a steady slow increase in target 
cell lysis over the entire 12 hr measurement period. The 
Figure 2: SPM-1 mediates lysis of a panel of CD19-bearing cell lines derived from various types of B cell malignancies. 
Dose response profiles from Redirected Lysis (RDL) assays performed with SPM-1 or control proteins plus ex vivo expanded MNCs from 
healthy donors. Calcein release assays as described in Methods. SEM cells were derived from a pro-B ALL, NALM-6 from a pre-B ALL, 
RAJI from a Burkitt’s Lymphoma, and ARH-77 from a multiple myeloma. MNCs were used at an 8 : 1 effector-to-target cell (E : T) ratio, 
corresponding to a net NK : target cell ratio of 2 : 1, because NK cells accounted for approx. 25 % of the expanded MNC population. 
SPM-1 concentrations in the reaction mixtures in pM units. Specific lysis plotted on the vertical axis was computed as explained in 
Methods. The control triplebody targeting HER2 failed to induce specific lysis at comparable concentrations as SPM-1, because this antigen 
was undetectable on the target cells used here. In combination with HER2-bearing targets this triplebody was active in positive control 
experiments, performed separately. Data points plotted here are mean specific lysis percentages ± standard error of the mean (SEM) from 
n = 4 to 5 separate experiments.
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Figure 3: SPM-1 mediates stronger lysis of primary lymphoma- and leukemia blasts from newly diagnosed patients 
than the therapeutic antibody Rituximab (MabThera®). Malignant cells from peripheral blood of newly diagnosed patients were 
used as targets in RDL and ADCC assays with SPM-1 and Rituximab, respectively. SPM-1 and Rituximab were present in the reaction 
volumes in the concentrations shown in pM units. NK cells were used at a net E : T ratio of 2 : 1, as defined for Fig. 2. Samples were 
from 1 patient with a mixed phenotype acute leukemia (MPAL(NOS); CD19+ CD20-); 2 patients with B-CLL (CLL: chronic lymphocytic 
leukemia; CD19+ CD20LOW); 1 patient with a Non-Hogkin Lymphoma (NHL; CD19+ CD20HIGH) and 1 patient with newly relapsed B-CLL 
(CD19+ CD20DIM). This patient had undergone 6 previous treatments with Rituximab. Insufficient primary material from this patient was 
available to perform the HER2-16-HER2 control, which is indicated by an asterisk (*).
Table 3: Target antigen densities and EC50 values for RDL / ADCC by SPM-1 or rituximab with primary lymphoma 
and leukemia blasts isolated from newly diagnosed patients
Patient
Antigen density [#] EC50 [pM]
CD19 CD20 SPM1 Rituximab
B-CLL 1 (at diagnosis) 9,600 ± 500 4,000 ± 100 15.8 247.5
B-CLL 2 (at diagnosis) 7,600 ± 1,900 3,900 ± 1,200 3.0 1,300
Relapsed B-CLL 6,500 ± 1,700 1,800 ± 300 27.0 -
MPAL(NOS) 8,400 ± 2,800 0 86.0 -
NHL 14,600 ± 7,700 19,400 ± 2,200 35.7 185.7
Antigen densities are given in copy numbers per cell.
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control triplebody SPM-2 with binding sites for antigens 
CD33 and CD123 [27, 34], which were not expressed on 
these targets, did not cause target cell lysis beyond the 
spontaneous antibody-independent lysis (AIC) of this 
batch of γδ T cells alone (Figure 6). Lysis mediated by 
SPM-1 showed a faster initial rise than lysis mediated 
by the Fc-optimized antibody 4G7SDIE, although 
towards the end of the measurement period the reaction 
rates mediated by both agents appear to have stabilized 
and to have reached close to constant values. The raw 
Figure 4: Triplebody SPM-1 performs equally well as other best-in-class CD19-specific agents in related molecular 
formats in comparative RDL/ADCC assays. A. Asterisks indicate positions of point mutations (substitutions S239D and I332E) in 
the Fc region of the Fc-engineered antibody 4G7SDIE. Single chain fragment variable (scFv) units used in the minibody and the triplebody 
are labeled. One minibody carried the non-engineered Fc-domain, the other the same 2 mutations S239D and I332E shown above for 4G7 
SDIE plus a third substitution A330L (third asterisk). B. RDL analysis of SPM-1 (filled black circles) compared with the best-in-class 
antibody 4G7SDIE (open triangles), the Fc-engineered minibody (open circles) and the non-engineered minibody (black squares). Target 
cells: SEM (top) and Namalwa (bottom).
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data for Donor 4 from this experiment are also shown 
in Supplementary Figure S1, because this representation 
visualizes in a particularly clear manner that the lytic 
process as followed by this assay did not proceed with 
a mono-phasic, but with an at least bi-phasic kinetics. 
This observation suggests that at least 2 different so far 
unknown molecular processes are at work at different 
stages of the overall reaction. In the Discussion section 
we attempt to relate these results to the different molecular 
architecture of these antibody-derived agents.
DISCUSSION
The key findings of this study are: 
• The humanized and optimized triplebody SPM-1 can 
be produced in sufficient quantity and purity with an 
industry standard production and purification process, 
which can be scaled up for large-scale production.
•  SPM-1 mediated efficient redirected lysis of CD19-
bearing target cells in cell culture assays not only by 
NK cells but also by γδ T cells from healthy donors.
•  In benchmark experiments with NK cells from healthy 
donors, SPM-1 was equally active as Fc-engineered 
antibody-derived proteins, including the CD19 
antibody 4G7SDIE. It was active at similarly low EC50 
concentrations in the picomolar range and mediated 
comparable maximum specific lysis as these best-in-
class reference proteins.
• SPM-1 mediated efficient lysis of primary cells from 
patients with various B lineage malignancies and of 
cell lines derived from various B cell neoplasms by NK 
cells from healthy donors. The agent produced stronger 
ADCC lysis than Rituximab of primary cells from 3 
Figure 5: Primary γδ T cells are activated for cytolysis by exposure to SPM-1 plus target cells. A. Fresh γδ T cells were 
prepared from healthy donors as described in Methods and exposed to SPM-1 with or without NALM-6 or SEM target cells. Degranulation 
of γδ T cells was monitored indirectly by cytofluorimetric measurement of the surface antigen density of the degranulation marker CD107a. 
B. Changes in intracellular TNFα concentrations in primary γδ T cells following exposure to SPM-1 plus/minus target cells were measured 
cytofluorimetrically as described in Methods. C. Changes in intracellular IFN-γ concentrations in primary γδ T cells occurring after exposure 
to SPM-1 plus/minus target cells were measured cytofluorimetrically as described in Methods. Of the 6 samples from different donors that 
were analyzed, 4 had a γδ T cell content above 2 % in their PBMC compartments and each of these responded to exposure to SPM-1 plus 
target cells by increased cytokine production and increased surface exposure of the degranulation marker in comparison to treatment with 
the control triplebody SPM-2 or exposure to the target cells alone without mediator proteins.
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B-CLL patients, one NHL patient and one MPAL 
(NOS) patient. 
• Non-expanded γδ T cells from freshly drawn PBMC 
samples of healthy donors were activated for cytolysis 
by exposure to SPM-1 plus target cells, as evidenced by 
surface exposure of the degranulation marker CD107a 
and elevated intracellular concentrations of TNFα and 
IFN-γ. 
• SPM-1 mediated lysis of surface-adherent target 
cells by both non-expanded and ex vivo expanded γδ 
T cells from healthy donors in the impedance-based 
xCelligence assay. 
• In the xCelligence assay, SPM-1 mediated a rapid 
initial phase of lysis of surface-bound targets, faster 
than lysis mediated by the Fc-engineered reference 
antibody 4G7SDIE.
The humanized and optimized triplebody SPM-
1 was equally potent in ADCC as the parental agent, 
and its production and purification by industry-standard 
procedures routinely used for commercial production 
of therapeutic antibodies was found to be possible. The 
ADCC assays presented here were performed with ex 
vivo expanded NK cells from healthy donors, which 
were pre-activated through long-term exposure to IL-
2. We anticipate that SPM-1 will also be active in 
patients with B-lymphoid malignancies by directing 
autologous NK cells, provided it is administered at a 
time, when endogenous NK cells are present in sufficient 
numbers and are cytolytically active. This is the case for 
example for pediatric patients with acute lymphoblastic 
leukemia in a post-transplant setting a few weeks after 
transplantation, where donor-derived NK cells rapidly 
reconstitute the patient's blood and marrow and are active 
in mediating graft-versus-leukemia (GvL) effects [37]. 
Figure 6: SPM-1 directs expanded γδ T cells from healthy donors for very rapid lysis of CD19-bearing MCF7-CD19 
tm target cells, monitored in a real-time assay. For γδ T cell donors # 2, 3 and 4 specific lysis curves were calculated from the cell 
indices (CI) of MCF7-CD19 tm cells, measured over the time course of the reaction with 1 nM SPM-1 or control proteins. SPM-2: control 
triplebody 33-16-123 with scFv binding domains for the target antigens CD33 and CD123, which are not carried by the MCF7-CD19 tm 
cells. CI values measured after treatment with control triplebody SPM-2 were comparable to those obtained with γδ T cell controls alone. 
Measurements were performed with the help of the label-free impedance-based xCelligence assay as described in Methods. Decreasing CI 
values are a correlate of and indicative of target cell lysis. In the presence of triplebody SPM-1, CI values decreased to approximately 9-fold 
lower values than after treatment with γδ T cells alone (Patient 4: 0.1 versus 0.9). Furthermore, specific lysis upon treatment with SPM-1 
was more rapid and efficient than after treatment with ADCC-optimized CD19-antibody 4G7SDIE.
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It remains, however, to be demonstrated in experiments 
with autologous NK cells from patients not treated 
by a stem cell transplant, that these cells also achieve 
a sufficiently strong ADCC lysis of their cancer cells 
mediated by SPM-1. Corresponding studies have been 
performed for triplebody SPM-2, which mediated ADCC 
of a patient's AML cells by autologous NK cells, when 
these were drawn in first remission after a successful 
induction therapy [34]. The issue is still debated, because 
in AML autologous NK cells have been reported to be 
reduced in numbers and specific lytic potential in the 
tumor environment [19–22]. It is not clear, whether this 
reversible functional attenuation is equally important 
in B-lymphoid malignancies as in AML, because it is 
supposedly mediated at least in part by soluble mediators 
and the hypoxic milieu present in the marrow of AML 
patients. The tumor environment may be quite different 
for B-lymphoid malignancies, which evolve at different 
sites and in different cellular environments. We do not yet 
know, whether γδ T cells are present in sufficient numbers 
and in an active state for ADCC in patients with B cell 
malignancies at the sites of the cancer cells.
Triplebodies such as SPM-1 achieve similar 
cytotoxic effects as conventional therapeutic antibodies 
in cell culture ADCC assays in far lower concentrations. 
Rituximab for example is used in lymphoma therapy 
at concentrations in the range of 10 mg/kg, while 
Blinatumomab is used at concentrations in the range of 
10 μg/kg, i.e. in approximately 1.000-fold lower doses 
[11]. In the results presented above with primary cells 
from patients with B cell malignancies (Figure 3), SPM-1 
was active in ADCC assays in concert with NK cells with 
EC50-values lower by 5- to 430-fold than those determined 
for Rituximab. This finding is consistent with the dose 
ranges of Rituximab and Blinatumomab used in clinical 
applications as quoted above. The primary cells from 
the relapsed B-CLL patient, which were not efficiently 
lysed by NK cells plus Rituximab (Figure 3), were not 
antigen-loss variants and still expressed surface CD20. 
More likely, they were resistant to ADCC by NK cells 
through a different mechanism. Such cases have been 
reported for other Rituximab-resistant patients. However, 
this resistance cannot have been a general resistance to 
all different pathways leading to death of target cells by 
ADCC, because the cells were still lysed by ADCC via 
NK cells plus SPM-1.
The Fc-engineered CD19 antibody 4G7SDIE, 
which is largely identical with the corresponding 
antibody XmAb5574 [9, 39, 41], has previously been 
shown to mediate potent ADCC by γδ T cells [41]. 
This T cell subset is particularly useful in combination 
with TCRαβ- and CD19-depleted allogeneic stem cell 
transplantation (allo-HSCT) [47]. In such cases, both 
γδ T cells and NK cells are available for graft-versus-
leukemia activity and can maintain a certain level of 
immune protection of the host. The γδ T cell population 
is small but potent, and does not only provide a natural 
anti-cancer activity, but is also unlikely to elicit graft-
versus-host-disease (GvHD), because of its independence 
from MHC-restriction. Furthermore these cells mediate 
significant anti-viral activity. Therefore, γδ T cells are a 
highly desirable population of immune effector cells for 
cancer immunotherapy [37, 38]. The results presented 
here establish that the CD16-binding module carried in 
SPM-1 is capable of engaging both NK and γδ T cells as 
effectors for lysis of leukemia cells. Efficient activation 
and engagement of γδ T cells by SPM-1 was demonstrated 
here, and the potential expansion of this leukocyte subset 
in vivo in response to activation holds promise for the 
treatment of leukemia patients with triplebodies triggering 
γδ T cells via CD16.
The most unexpected new finding of the present 
study was produced with the help of the xCelligence 
assay, which allowed us to follow a cytolytic reaction 
mediated by a triplebody in real time. The following 
unresolved problem has intrigued us for several years: 
the parental triplebody ds(19-16-19) of SPM-1 showed an 
approximately 3-fold stronger binding avidity to CD19 on 
leukemic target cells than the bispecific tandem diabody 
19-16, but had an approximately 25-fold greater cytolytic 
potential than this diabody for a number of malignant 
B-lymphoid cell lines and primary cell samples from a 
number of patients with different B-lymphoid cancers 
[26]. It was hypothesized that the triplebody may have led 
to the formation of a tighter synapse between the cancer 
cells and the NK cells, and that this in turn may have 
led to a stronger activation of the NK cells for cytolysis. 
However, no direct evidence in support of this hypothesis 
has been produced, because structural methods for a 
comparative analysis of the fine structure of the synapses 
produced by both agents were not available. It came as a 
surprise that progress towards solving this problem may 
come from improving the resolution of measurement 
methods for kinetic aspects of synapse formation and the 
cytolytic reaction.
The key observation reported here (Figure 6; 
Supplementary Figure S1) is that the cytolytic reaction, as 
followed by the xCelligence assay, occurred with a biphasic 
kinetic or a kinetic of even greater complexity. A rapid 
initial change in the cell index (CI), a measure of viability 
of the cells (equated with a rapid first phase of cellular lysis 
[42]), was followed by at least one more phase of slower 
viability changes. We do not know the precise correlation 
between the changes in the CI-value and cellular death, 
and whether a change in CI is only achieved when a target 
cell is completely lysed, or whether it also occurs, when 
a target cell is not yet irreversibly dead, but has engaged 
in the first steps of a multi-step pathway to death. Cell 
death mediated by NK cells through the degranulation of 
granzymes is death by apoptosis, and occurs through a 
succession of steps, which can be individually monitored. 
An example in case is the time-resolved study of apoptosis 
by cytofluorimetry with staining of the target cells by 
annexin V and propidium iodide [48]. In this case an early 
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pre-apoptotic phase can be distinguished, characterized by 
annexin V staining but yet no influx of PI into the nucleus, 
which is still reversible. A subsequent late apoptotic state is 
characterized by more intense staining with both annexin 
V and PI, which is irreversible. It is not clear, whether the 
initial rapid change in the CI-value, which was observed 
here, reflects a truly irreversible step towards cellular death 
and complete lysis, mediated by γδ T cells, or only a change 
in impedance, which may be associated with reversible pre-
apoptotic changes such as the rearrangements of the cellular 
membrane detected by binding of annexin V. Regardless 
of the precise correlation between events discovered by 
changes in CI in this assay and progressive stages on the 
path to cellular death as detected by other methods, the data 
shown here demonstrate the existence of more than one so 
far poorly understood reaction phases, which are likely to 
be highly informative about the mechanism of action of this 
triplebody.
A potential answer to the problem posed above, 
suggested by the results of the present study is that the 
strength of binding of a therapeutic protein to the target 
cell may not be the dominant determinant of its cytolytic 
potential. To build a productive cytolytic synapse, 
binding of the agent to the trigger on the effector cell is 
also important. Although the binding affinities of SPM-
1 for CD16 on effector cells and of the CD16 receptor 
on effector cells for the Fc-domain of Fc-engineered 
antibodies such as 4G7SDIE are in the same order of 
magnitude, it is still possible that the triplebody has faster 
access to CD16 on the γδ T cell (and thus a faster “on”-
rate) than the 4G7SDIE antibody. We suspect this to be the 
case, because the triplebody has only half the mass of the 
antibody and may have different space-filling properties 
and different flexibility, which may allow faster access to 
the CD16 epitope on the effector cell. This faster access 
may lead in turn to a faster formation of a synapse between 
the suface-adherent target cells and the triplebody-
decorated γδ T cells. This could lead to the differences in 
the initial phase of changes in the CI index, which were 
detected by the xCelligence assay. This difference in the 
early stage of the kinetics may not affect the EC50-values 
and the degree of maximum specific lysis, because both 
SPM-1 and the 4G7SDIE antibody mediated target cell 
lysis by NK cells with similar EC50-values and similar 
maximum specific lysis (Figure 4B). It could however 
still have an impact on the pharmacokinetic properties 
of both agents, and thus on their anti-cancer activities in 
vivo. Therefore, the xCelligence assay offers a welcome 
enrichment of the set of tools available to study cytolytic 
processes in detail, even if it still does not allow for single 
cell resolution. Combining high throughput real-time 
assays with single-cell resolution assays is an important 
area for future improvements, which promises to be highly 
informative [49].
Taken together, the data presented here permit us 
to conclude that SPM-1 in combination with NK cells is 
highly active in ADCC reactions against primary cells 
from patients with a variety of B-lymphoid malignancies. 
It is capable of recruiting γδ T cells for cytolysis, and 
reveals unsuspected rapid reaction kinetics in time-
resolved cytolysis assays. These properties make it both 
a valuable tool for further studies of the kinetics of the 
cytolytic process together with CD16-bearing effector 
cells, and a candidate for further clinical development as a 
highly potent alternative for the treatment of B-lymphoid 
malignancies with distinct advantages over available best-
in-class agents.
MATERIALS AND METHODS
Generation of triplebodies and other antibodies 
and antibody-derived proteins
To produce triplebody SPM-1, the CD19-specific 
scFv domains contained in the parental triplebody 
ds(19-16-19) [26] were humanized with procedures 
developed in the laboratory of Dr. A. Honegger [43, 
44]. The CD16-specific scFv was disulfide-stabilized 
according to published procedures [43]. SPM-1 
contains a C-terminal hexa-histidine tag for purification 
purposes. Potentially immunogenic sequences that 
resulted from the standard cloning procedures used 
for the generation of the parental ds(19-16-19) were 
removed from the final protein. The coding sequence 
for SPM-1 was optimized to minimize homologous 
recombination between cDNA sequences coding for 
the CD19 binding domains by introducing variations 
in the wobble bases of the coding triplets. The cDNA 
was subcloned into a pSecTag2-HygroC expression 
vector (Life Technologies, Darmstadt, Germany). The 
Her2-16-Her2 triplebody was constructed by replacing 
the N- and C-terminal scFvs of a humanized successor 
molecule of the published triplebody ds(19-16-19) [26] 
with Her2-specific scFvs from the pSecTag2-HygroC-
4D5-CD3 bispecific single chain Fv construct provided 
by Prof. M. Peipp [50] using standard molecular 
biology techniques.
The minibodies 4D5-IgG1-Fc and 4D5-IgG1-Fc 
engineered (provided by Prof. M. Peipp) contained a Her2 
(clone 4D5)-specific scFv, a modified hinge region from an 
IgG, which allowed for disulfide-bridge formation, and a 
modified Fc-domain, harboring the substitutions S239D/
I332E/A330L (SDIEAL) or no substitutions, respectively 
[50]. To generate the CD19-targeting minibodies, the 4D5-
scFv was replaced by the CD19-targeting scFv from SPM-1.
For the expression of all proteins, human FreestyleTM 
293-F cells (Life Technologies, Darmstadt, Germany) 
were transfected with the respective plasmid DNA using 
the 293fectinTM Transfection Reagent (Life Technologies, 
Darmstadt, Germany) according to the manufacturer´s 
instructions. Proteins were either expressed transiently 
or a pool of stably transfected cells was generated by 
continuous selection with 50 µg/ml hygromycin C.
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Recombinant proteins were captured from cell 
culture supernatants via their C-terminal hexahistidine 
tags by metal-ion affinity chromatography. SPM-1 
was further purified by anion- and cation-exchange 
chromatography. The scFv-minibodies and Her2-16-Her2 
were further purified by size exclusion chromatography. 
Protein concentrations were determined by absorbance 
measurements at 280 nm and using the molar extinction 
coefficient derived from the amino acid sequence.
The quality of purified recombinant protein batches 
was analyzed by analytical size exclusion chromatography 
to monitor the presence of monomeric protein, aggregates, 
breakdown products, incompletely synthesized products, 
contaminants and products generated by homologous 
recombination. An Äkta liquid chromatography system 
was used, equipped with a Superdex S200 5/150 GL 
column (GE Healthcare Europe, Munich, Germany). Total 
amounts of 25 µg of protein in 50 µl volumes were loaded 
onto the column followed by isocratic elution with SEC 
buffer (20 mM Histidine-HCl pH 6.0, 150 mM NaCl). 
Eluted proteins were monitored by absorbance at 280 nm 
and by SDS-PAGE.
The CD19 antibody 4G7SDIE was provided by Prof. 
G. Jung and Dr. L. Grosse-Hovest from the University of 
Tübingen, Germany. This antibody harbors an engineered 
Fc-domain with the same substitutions S239D and I332E 
as the CD19 antibody XmAb 5574 [9, 39, 41]. The 
therapeutic CD20 antibody Rituximab (MabThera®) was 
obtained from Roche Pharma AG.
Target cells and culture conditions
The RAJI, NALM-6, SEM, NAMALWA, ARH-77 
and MCF-7 cell lines were obtained from the German 
Collection of Microorganisms and Cell Cultures (DSMZ, 
Braunschweig, Germany). RAJI, NALM-6, NAMALWA 
and ARH-77 were cultured in RPMI 1640 medium 
(Invitrogen, Karlsruhe, Germany). MCF-7 and SEM cells 
were kept in EMEM and IMDM medium (Lonza, Basel, 
Switzerland), respectively. All media were supplemented 
with 10 % fetal calf serum or pooled human AB serum 
(Invitrogen, Karlsruhe, Germany), 100 U/ml penicillin, 
100 µg/ml streptomycin, 1 mM sodium pyruvate and 2 
mM L-glutamine (all reagents from Biochrome).
MCF-7-CD19 tm cells were generated as described 
[41]. Briefly, full-length cDNA coding for human CD19 
(GenBank BC006338.2) was purchased from Source 
Bioscience (Berlin, Germany) and cloned into a suitable 
cDNA expression vector. MCF-7 cells were transfected 
with this plasmid by electroporation, and CD19-expressing 
clones were selected and sorted by flow cytometric 
analysis, respectively.
Preparation of primary cells from blood of 
human donors
Peripheral blood samples were drawn from subjects 
into EDTA solution at the Medical Center of the LMU 
Munich or isolated from platelet-pheresis products 
provided by the Institute for Transfusion Medicine of 
the University of Tübingen after receiving informed 
written consent. The project was approved by the Ethics 
Committee of the University of Munich Medical Center. 
Mononuclear cells (MNCs) from leukemia patients 
and healthy donors were enriched by density gradient 
centrifugation using the Lymphoflot reagent (Biotest, 
Dreieich, Germany) or Biocol Separating Solution 
(Biochrom, Berlin, Germany) according to manufacturer’s 
instructions. PBMCs, also used as the source of leukemia 
cells from patient samples, were then either suspended in 
RPMI medium (Life Technologies) containing 10 % fetal 
bovine serum (FBS) with penicillin and streptomycin (PS) 
at 100 units/ml and 100 µg/ml, respectively, for immediate 
use, or stored frozen in a solution containing 90 % FBS 
and 10 % DMSO. Cell viability was assessed by Trypan 
blue exclusion before use.
Ex vivo expansion of MNCs as a source of NK 
cells from healthy donors
PBMCs were expanded ex vivo in RPMI medium 
containing Interleukin-2 (IL-2) plus 5 % human serum 
(Life Technologies) for 20 d after an initial period of 
culture in the presence of an OKT3 (CD3) antibody, 
and were then frozen in aliquots for subsequent use as 
described [30, 51]. Prior to use in cytolysis experiments, 
the cells were thawed and cultured overnight in RPMI 
medium containing 5 % human serum plus 50 units/ml 
and 50 µg/ml PS, respectively, but no additional IL-2.
Expansion of γδ T cells
PBMCs were seeded at 1.5 x 106 cells per well 
in 6-well plates and cultured in supplemented IMDM 
medium containing 100 IU/ml of recombinant human 
IL-2 (rhIL-2) (Novartis, Basel, Switzerland) and 400 
nM zolendronate (Hexal, Holzkirchen, Germany). After 
13 - 14 d of culture, expanded populations containing 
35.9 - 60.6 % of γδ T cells were positively selected 
using a Hapten-modified TCR-γδ antibody and FITC-
conjugated anti-Hapten MicroBeads with the autoMACS 
system (Miltenyi, Bergisch Gladbach, Germany). Purity 
of the isolated populations was (99.2 ± 0.8) % (n = 3) 
and isolated cells were incubated with 400 IU/ml rhIL-2 
overnight prior to functional assays. Isolated γδ T cells 
had lost their FITC-labeling and had restored surface 
expression of TCR-γδ after 24 hrs (U Seidel, unpublished 
data).
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Flow cytometric analysis
Flow cytometric analysis was performed with an 
Accuri C6 flow cytometer (BD Biosciences, Heidelberg, 
Germany). CD16- and CD56-specific monoclonal 
antibodies (mAbs) were used for the analysis of NK cell 
content in PBMC-preparations and measured against 
isotype control mAbs (Immunotech, Marseille, France). 
Unlabelled CD19- and CD20-specific and isotype control 
mAbs (BD Pharmingen) were used for the analysis of 
cell surface densities of the antigens on target cells. 
Surface expression was measured using a calibrated 
cytofluorimetric assay (QIFI KIT®; DAKO; Hamburg, 
Germany) as described [45, 52].
Determination of equilibrium binding constants 
(KD) and serum stability measurements of SPM-
1
Equilibrium binding constants (KD values) were 
measured using a flow cytometry method as previously 
described [46]. The KD values were calculated from the 
raw data by using a nonlinear regression curve fit with the 
help of GraphPad Prism 3 (Graph Pad Software, Inc, San 
Diego, CA). Measurement of in vitro stability of SPM-1 in 
human serum was performed as previously described [26].
Redirected lysis (RDL) assays using calcein 
release
Non-radioactive cytolysis assays based on the 
release of calcein from target cells were performed 
as previously described [30]. Calcein AM (Life 
Technologies)-labeled target cells were mixed with 
effector cells (ex vivo expanded MNCs) in RPMI 1640 
GlutaMAX medium supplemented with 10 % FCS and 1 
% Penicillin/Streptomycin at an E (NK cell) : T ratio of 
2 : 1. After addition of different concentrations of SPM-1 
or control antibodies and antibody derivates (minibodies), 
respectively, reactions were incubated at 37 °C with 5 % 
CO2 for 3 - 4 hrs. Calcein release was then determined by 
measuring the fluorescence intensity (relative light units, 
RLU) in the supernatant with a Tecan Infinite M1000 
microplate reader (Tecan Group Ltd, Männedorf) at 
485/535 nm. Maximum lysis was achieved by addition 2.5 
% Triton X-100. Specific lysis was calculated as follows:
Specific Lysis
RLU sample RLU background release
RLU lysis RLU background
%   100*
[  ( )   ]
[  (max )  ( )]
( )
=
−
−
EC50-values (concentration of triplebody producing 50 
% of maximum specific lysis) were determined using 
sigmoidal dose-response curve fits (GraphPadPrism, San 
Diego, CA).
γδ T cell degranulation assay using detection of 
cell surface CD107a
The fraction of γδ T cells (CD3+, TCRγδ+) was 
determined by flow cytometry. Samples with γδ T cell 
counts above 1.5 % were selected for CD107a assays. 
Equal numbers of PBMC and NALM-6 or SEM cells were 
incubated with 1 nM SPM-1 or control triplebody Her2-
16-Her2, 2 µM GolgiStop reagent (BD Biosciences), 10 
µg/ml Brefeldin A (Sigma, Steinheim, Germany) and the 
fluorescent labeled CD107a-APC antibody (Biolegend, 
San Diego, USA) overnight in supplemented IMDM 
medium at 37 °C in an incubator with a 5 % CO2-
atmosphere. PBMCs were then stained for surface and 
intracellular markers and analyzed by flow cytometry.
Intracellular cytokine staining (ICS) of γδ T cells 
for TNFα and IFN-γ
Intracellular cytokine staining of γδ T cells was 
performed with IFNγ-BV711, TNFα-PB, and isotype 
control antibodies supplied by Biolegend (San Diego, 
CA, USA). Briefly, after incubation of γδ T cells with 
SEM or NALM-6 cells and SPM-1 triplebody or controls, 
cells were washed and resuspended in 100 µl of PBS : 
1 % albumin solution. Cells were then stained with γδ 
TCR mAb (BD Biosciences, Heidelberg, Germany) for 
30 min on ice. To distinguish TNFα and IFN-γ producers 
within the γδ T cell populations, cells were washed, 
fixed and permeabilized by incubation with 250 µl of 
Cytofix/Cytoperm solution (BD Biosciences, Heidelberg, 
Germany) for 15 min. Cells were then stained with either 
PE conjugated TNFα or IFN-γ mAbs versus a control mAb 
for 30 min on ice. The cells were finally washed twice, 
resuspended in FACS buffer (PBS containing 2 % fetal 
calf serum (FCS) plus 0.05 % sodium azide) and analyzed 
by flow cytometry. The percentage of cytokine-positive 
cells within the given γδ T cell treatment group was then 
calculated and plotted.
Impedance-based cytotolysis assay with human 
γδ T cells as cytolytic effectors
The cytolytic potential of expanded γδ T cells 
was analyzed in a real-time cytotoxicty assay with an 
xCelligence RTCA SP instrument (ACEA Biosciences, 
San Diego, CA) as previously described [41, 42]. Briefly, 
5x103 MCF-7-CD19 tm cells were seeded into each 
well. Expanded γδ T cells and 1 nM SPM-1 or control 
triplebody Her2-16-Her2, respectively, were added 24 hrs 
later. Cell viability was monitored every 15 min for 48 
hrs. Cell indexes (CI) were normalized to CI of the time-
point, when γδ T cells were added, and specific lysis was 
calculated relative to control cells without any added γδ 
T cells.
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